NO20074052L - Prosesser for a fremstille pyrazol[3,4-D]pyrimidinetere - Google Patents

Prosesser for a fremstille pyrazol[3,4-D]pyrimidinetere

Info

Publication number
NO20074052L
NO20074052L NO20074052A NO20074052A NO20074052L NO 20074052 L NO20074052 L NO 20074052L NO 20074052 A NO20074052 A NO 20074052A NO 20074052 A NO20074052 A NO 20074052A NO 20074052 L NO20074052 L NO 20074052L
Authority
NO
Norway
Prior art keywords
processes
preparing pyrazole
pyrimidine
pyrimidine ethers
ethers
Prior art date
Application number
NO20074052A
Other languages
English (en)
Inventor
Tawfik Gharbaoui
Dipanjan Sengupta
Edward A Lally
Naomi S Kato
Marlon Carlos
Natalie Rodriguez
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of NO20074052L publication Critical patent/NO20074052L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelse angår fremgangsmåter for fremstilling av pyrazolo[3,4-d]-pyrimidineter-forbindelser som er modulatorer av glukosemetabolisme og derfor anvendelige ved behandling av metabolittiske forstyrrelser slik som diabetes og fedme.
NO20074052A 2005-01-13 2007-08-06 Prosesser for a fremstille pyrazol[3,4-D]pyrimidinetere NO20074052L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64371205P 2005-01-13 2005-01-13
PCT/US2006/001020 WO2006076455A2 (en) 2005-01-13 2006-01-12 Processes for preparing pyrazolo[3,4-d]pyrimidine ethers

Publications (1)

Publication Number Publication Date
NO20074052L true NO20074052L (no) 2007-09-12

Family

ID=36463499

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074052A NO20074052L (no) 2005-01-13 2007-08-06 Prosesser for a fremstille pyrazol[3,4-D]pyrimidinetere

Country Status (22)

Country Link
US (1) US7425630B2 (no)
EP (1) EP1838713A2 (no)
JP (1) JP2008526975A (no)
KR (1) KR20070114126A (no)
CN (1) CN101142216A (no)
AR (1) AR052557A1 (no)
AU (1) AU2006204940A1 (no)
BR (1) BRPI0606115A2 (no)
CA (1) CA2593345A1 (no)
CR (1) CR9224A (no)
DO (1) DOP2006000009A (no)
EA (1) EA013968B1 (no)
GT (1) GT200600011A (no)
HN (1) HN2006001493A (no)
IL (1) IL184365A0 (no)
MX (1) MX2007008381A (no)
NO (1) NO20074052L (no)
PA (1) PA8659701A1 (no)
PE (1) PE20061118A1 (no)
TW (1) TW200637865A (no)
WO (1) WO2006076455A2 (no)
ZA (1) ZA200705279B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
TWI335328B (en) * 2003-07-14 2011-01-01 Arena Pharm Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto
US7923465B2 (en) * 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
JP5498392B2 (ja) 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
MX2011000664A (es) * 2008-07-16 2011-02-24 Schering Corp Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119.
CN102143965A (zh) 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
PT2414363E (pt) 2009-03-31 2014-02-26 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
US20100285145A1 (en) * 2009-05-08 2010-11-11 Pfizer Inc Gpr 119 modulators
KR20120061063A (ko) * 2009-06-05 2012-06-12 화이자 인코포레이티드 Ｇｐｒ 119 조절제로서의 ｌ-(피페리딘-4-일)-피라졸 유도체
CA2786994C (en) 2010-01-27 2018-01-16 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
UA110347C2 (uk) 2010-08-12 2015-12-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
AU2012267556B9 (en) 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
JP6567276B2 (ja) * 2014-05-13 2019-08-28 ソニーセミコンダクタソリューションズ株式会社 固体撮像素子、および電子機器
US10300064B2 (en) * 2014-12-06 2019-05-28 Intra-Cellular Therapies, Inc. Organic compounds
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
JP2019122134A (ja) 2018-01-04 2019-07-22 Ntn株式会社 スイッチング電源の力率改善用ｐｗｍ制御装置
AU2019280822A1 (en) 2018-06-06 2021-01-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
MX2023014547A (es) * 2021-06-23 2024-04-29 Hoffmann La Roche Proceso para la preparacion de inhibidores de familia de receptores tipo nod con dominio pirina 3 (nlrp3).

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981003174A1 (fr) 1980-04-28 1981-11-12 Teijin Ltd Derives de thiazolo (3,2-a) pyrimidine, leur procede de preparation, et medicaments les contenant
EP0053678A1 (de) 1980-12-05 1982-06-16 BASF Aktiengesellschaft 5-Amino-1-phenyl-4-cyanpyrazole, diese enthaltende herbizide Mittel, Verfahren zu ihrer Herstellung und ihre Anwendung als Herbizide
US4612376A (en) 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
JP4022271B2 (ja) * 1995-10-31 2007-12-12 富士フイルム株式会社 ピラゾリルアゾフエノール色素
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
KR20020088406A (ko) * 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 치료제로서의 피라졸로피리미딘
DE10219435A1 (de) * 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
WO2004009602A1 (en) * 2002-07-23 2004-01-29 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
TWI335328B (en) * 2003-07-14 2011-01-01 Arena Pharm Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto
GB0425035D0 (en) * 2004-11-12 2004-12-15 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CA2593345A1 (en) 2006-07-20
ZA200705279B (en) 2008-11-26
IL184365A0 (en) 2007-10-31
WO2006076455A8 (en) 2006-11-02
AU2006204940A1 (en) 2006-07-20
US7425630B2 (en) 2008-09-16
DOP2006000009A (es) 2006-08-15
PA8659701A1 (es) 2006-09-08
US20060154940A1 (en) 2006-07-13
GT200600011A (es) 2006-08-10
WO2006076455A2 (en) 2006-07-20
JP2008526975A (ja) 2008-07-24
PE20061118A1 (es) 2006-10-13
BRPI0606115A2 (pt) 2009-06-02
EA013968B1 (ru) 2010-08-30
HN2006001493A (es) 2010-08-19
AR052557A1 (es) 2007-03-21
EA200701500A1 (ru) 2007-12-28
MX2007008381A (es) 2007-09-07
EP1838713A2 (en) 2007-10-03
CN101142216A (zh) 2008-03-12
KR20070114126A (ko) 2007-11-29
TW200637865A (en) 2006-11-01
CR9224A (es) 2007-10-23
WO2006076455A3 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
TW200637865A (en) Processes for preparing pyrazolo[3,4-d]pyrimidine ethers
NO20090064L (no) Pyrasoler som glucokinase aktivatorer
WO2008070692A3 (en) Bicyclic compounds and use as antidiabetics
MX2007007174A (es) Derivados de cicloalquilamina.
TW200637845A (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2004076413A3 (en) Phenyl- and pyridylpiperidine-derivatives as modulators of glucose metabolism
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
WO2005086860A3 (en) Methods for generating insulin-producing cells
TW200610528A (en) Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2007109211A8 (en) 1-oxo-isoindoline compounds for the treatment of spinal muscular atrophy and other uses
NO20074872L (no) Pyrazoler
TW200637844A (en) Processes for preparing aromatic ethers
WO2006127898A3 (en) (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
NO20080372L (no) Pyrazolderivater som teraputiske midler
NO20065936L (no) Sulfonyletylfosfordiamidater for anvendelse ved behandling av cancer.
GB0508318D0 (en) Organic compounds
JO2749B1 (en) Indole-2-Wen derivatives bilaterally substituted at position 3, their preparation and therapeutic application
EA200870606A1 (ru) Серосодержащие производные пиразола в качестве избирательных антагонистов рецептора каннабиноидов св
WO2006122777A3 (de) Verwendung von 2,5-disubstituierten thiazol-4-on-derivaten in arzneimitteln
UA87026C2 (ru) СПОСОБ ПОЛУЧЕНИЯ ПИРАЗОЛО[3, 4-d]ПИРИМИДИНОВЫХ ЭФИРОВ
NZ593021A (en) Method of preparing deoxyribofuranose compounds
AU2003290418A1 (en) Novel molecules to develop drug for the treatment of osteoporosis
WO2007009704A3 (en) Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application